Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]APN-1607 PET in Alzheimer's Disease and Healthy Subjects
NCT04141150Phase 2Unknown
- Sponsor
- APRINOIA Therapeutics
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of florzolotau in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by APRINOIA Therapeutics. Primary endpoint: Assessment of [18F]APN-1607 Uptake Patterns by Regional SUVR Values at Day 7. Status: unknown.
02
Drugs
florzolotau
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04141150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141150.